Merck & Co. (MRK) : Boston Common Asset Management scooped up 19,655 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 163,870 shares of Merck & Co. which is valued at $8.8 Million.Merck & Co. makes up approximately 1.29% of Boston Common Asset Management’s portfolio.
Other Hedge Funds, Including , Risk Paradigm Group reduced its stake in MRK by selling 133 shares or 9.61% in the most recent quarter. The Hedge Fund company now holds 1,251 shares of MRK which is valued at $67,404. Merck & Co. makes up approx 0.09% of Risk Paradigm Group’s portfolio.Cutter Co Brokerage boosted its stake in MRK in the latest quarter, The investment management firm added 3,240 additional shares and now holds a total of 7,957 shares of Merck & Co. which is valued at $426,495. Merck & Co. makes up approx 0.19% of Cutter Co Brokerage’s portfolio.Bbva Compass Bancshares Inc reduced its stake in MRK by selling 2,112 shares or 1.58% in the most recent quarter. The Hedge Fund company now holds 131,697 shares of MRK which is valued at $7.1 Million. Merck & Co. makes up approx 0.53% of Bbva Compass Bancshares Inc’s portfolio.Chesley Taft Associates reduced its stake in MRK by selling 84 shares or 0.12% in the most recent quarter. The Hedge Fund company now holds 67,670 shares of MRK which is valued at $3.7 Million. Merck & Co. makes up approx 0.39% of Chesley Taft Associates’s portfolio.Argyle Capital Management reduced its stake in MRK by selling 480 shares or 0.5% in the most recent quarter. The Hedge Fund company now holds 96,381 shares of MRK which is valued at $5.3 Million. Merck & Co. makes up approx 2.37% of Argyle Capital Management’s portfolio.
Merck & Co. opened for trading at $53.77 and hit $54.77 on the upside on Monday, eventually ending the session at $54.65, with a gain of 1.43% or 0.77 points. The heightened volatility saw the trading volume jump to 66,49,085 shares. Company has a market cap of $151,273 M.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.